Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 249165
Corporate User License Price USD 10500
Corporate User License Price INR 747495
Site License Price USD 7000
Site License Price INR 498330
Request a Quote

Report Title

Glycoprotein 41 (gp41) - Pipeline Review, H2 2018

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Glycoprotein 41 (gp41) - Pipeline Review, H2 2018


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Glycoprotein 41 (gp41) - Pipeline Review, H2 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Glycoprotein 41 (gp41) - Pipeline Review, H2 2018



Executive Summary

Glycoprotein 41 (gp41)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Glycoprotein 41 (gp41)-Pipeline Review, H2 2018'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

Glycoprotein 41 (gp41)-Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41 fusion peptides with the target cell causes a formation of an intermediate structure which bridges and fuses the viral and host membranes together.

The report 'Glycoprotein 41 (gp41)-Pipeline Review, H2 2018' outlays comprehensive information on the Glycoprotein 41 (gp41) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 1, 1, 7 and 1 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 5 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glycoprotein 41 (gp41)

- The report reviews Glycoprotein 41 (gp41) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics and enlists all their major and minor projects

- The report assesses Glycoprotein 41 (gp41) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Glycoprotein 41 (gp41) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Glycoprotein 41 (gp41)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glycoprotein 41 (gp41) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Glycoprotein 41 (gp41)-Overview

Glycoprotein 41 (gp41)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Glycoprotein 41 (gp41)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glycoprotein 41 (gp41)-Companies Involved in Therapeutics Development

Amunix Operating Inc

Frontier Biotechnologies Inc

Longevity Biotech Inc

Minka Therapeutics SA

Mymetics Corp

Navigen Inc

Osel Inc

Sanofi Pasteur SA

Glycoprotein 41 (gp41)-Drug Profiles

albuvirtide LAR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CPT-31-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-007-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Enfuvirtide-XTEN-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HIV-1 vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

human immunodeficiency virus (virus like particles) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBT-5001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target GP120 and GP41 for HIV-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Target GP41 for HIV Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MYMV-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MYMV-201-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Peptides to Inhibit gp41 for HIV-1 Infection-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Glycoprotein 41 and Glycoprotein 120 for Infectious Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhbit GP41 for HIV Infections-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Inhibit GP120, GP41, Tat, Integrase and Protease for HIV-1 Infection-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAC-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VAC-3S-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VCP-2438-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glycoprotein 41 (gp41)-Dormant Products

Glycoprotein 41 (gp41)-Discontinued Products

Glycoprotein 41 (gp41)-Product Development Milestones

Featured News & Press Releases

Aug 21, 2018: Frontier Biotech's novel long-acting, all-injectable anti-HIV two-drug combo IND allowed by the US FDA

Jun 07, 2018: Frontier Biotech receives marketing authorization from China FDA for Aikening (albuvirtide for injection), China's first new drug for the treatment of HIV

Sep 18, 2017: Navigen Awarded USD 4.9MM to Advance its HIV Entry Inhibitor CPT31

Sep 13, 2017: Mymetics to Present New Preclinical Data on Thermostable and Cold-Chain Independent Virosome based Vaccines

Jul 26, 2017: Navigen Presents Promising Pre-Clinical Data on CPT31 at the 9th International AIDS Society Conference on HIV Science

Nov 28, 2016: First new HIV vaccine efficacy study in seven years has begun

Oct 20, 2016: Dr. Michael Kay Presents Recent Data on Navigen's HIV Entry Inhibitor, CPT31, at the 2016 HIVR4P meeting

Sep 19, 2016: Mymetics and Texas Biomedical Research Institute Continue Collaboration on HIV Vaccine Development

Aug 24, 2016: Navigen Awarded USD 500,000 Grant to Support Depot Formulation of its HIV Drug Candidate

Jun 06, 2016: Frontier Biotech Long-acting HIV-1 Fusion Inhibitor Albuvirtide Meets 48-Week Primary Objective: Interim Results of a Phase 3 Trial

May 20, 2016: InnaVirVax Obtained FDA Authorization for a Phase 2 Clinical Trial with VAC-3S in HIV Functional Cure in the US

May 18, 2016: Large-scale HIV vaccine trial to launch in South Africa

Apr 11, 2016: Mymetics' HIV vaccine candidate confirms promise in preclinical study with Texas Biomed

Jul 30, 2015: Encouraging results of the first clinical study of the VAC-3S vaccine against HIV, for which DIAXONHIT develops a companion diagnostic

Apr 30, 2015: Texas Biomed receives NIH grant to study papillomavirus-based AIDS vaccine

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Amunix Operating Inc, H2 2018

Pipeline by Frontier Biotechnologies Inc, H2 2018

Pipeline by Longevity Biotech Inc, H2 2018

Pipeline by Minka Therapeutics SA, H2 2018

Pipeline by Mymetics Corp, H2 2018

Pipeline by Navigen Inc, H2 2018

Pipeline by Osel Inc, H2 2018

Pipeline by Sanofi Pasteur SA, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Amunix Operating Inc

Frontier Biotechnologies Inc

Longevity Biotech Inc

Minka Therapeutics SA

Mymetics Corp

Navigen Inc

Osel Inc

Sanofi Pasteur SA

Glycoprotein 41 (gp41) Therapeutic Products under Development, Key Players in Glycoprotein 41 (gp41) Therapeutics, Glycoprotein 41 (gp41) Pipeline Overview, Glycoprotein 41 (gp41) Pipeline, Glycoprotein 41 (gp41) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person